GSK’s vaccine for severe RSV shows 43.3% effectiveness in third year
GSK Plc.’s single dose respiratory syncytial virus (RSV) vaccine for a severe form of the disease proved 43.3% effective in the third season
GSK Plc.’s single dose respiratory syncytial virus (RSV) vaccine for a severe form of the disease proved 43.3% effective in the third season
Sage Therapeutics Inc.’s experimental drug failed to meet its main goal of treating mild dementia due to Alzheimer's disease and the US, Cambridge-headquartered
Glaciers suffered the largest mass loss in 50 years as last year marked the driest for global rivers in 33 years, according to
HQ Team October 8, 2024:Humanity is hitting the upper limit of life expectancy, according to a new study. Medical advances have led to
Johnson and Johnson discontinued a study of an investigational drug to treat bladder cancer after it failed to yield desired results
HQ Team October 7, 2024: Rheumatoid arthritis (RA), an autoimmune disease that causes joint and bone inflammation, is affected by gut bacteria. Researchers
UK-based DIOSynVax, a biotechnology company, has developed a single candidate vaccine neutralizing immune responses across the spectrum of very diverse H5 subtypes of influenza
HQ Team October 7, 2024: The US Food and Drug Administration (FDA)has cleared Qnovia Inc’s nicotine inhaler RespiRx for clinical trial. The US
Extreme warming in the Antarctic Peninsula has increased the vegetation cover in the region by more than tenfold over the last four decades,